New hope for babies with dwarfism: weekly shot aims to boost growth

NCT ID NCT06079398

Recruiting now Disease control Sponsor: Ascendis Pharma A/S Source: ClinicalTrials.gov ↗

Summary

This study is testing a weekly injection called TransCon CNP in infants under 2 years old with achondroplasia, a genetic condition that causes short stature. The main goals are to see if the treatment is safe and if it helps children grow taller over 52 weeks. Infants will be randomly assigned to receive either the real injection or a placebo (a dummy injection with no medicine).

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ascendis Investigational Site
RECRUITING

Saint Paul, Minnesota, 55102, United States
Ascendis Investigational Site
RECRUITING

Houston, Texas, 77030, United States
Ascendis Investigational Site
RECRUITING

Madison, Wisconsin, 53705, United States
Ascendis Investigational Site
RECRUITING

Parkville, 3052, Australia
Ascendis Investigational Site
RECRUITING

Linz, 4020, Austria
Ascendis Investigational Site
RECRUITING

Copenhagen, 2100, Denmark
Ascendis Investigational Site
RECRUITING

Helsinki, 00029, Finland
Ascendis Investigational Site
RECRUITING

Paris, 75743, France
Ascendis Investigational Site
RECRUITING

Berlin, 13353, Germany
Ascendis Investigational Site
RECRUITING

Cologne, 50931, Germany
Ascendis Investigational Site
RECRUITING

Dublin, D01 YC76, Ireland
Ascendis Investigational Site
RECRUITING

Milan, 20132, Italy
Ascendis Investigational Site
RECRUITING

Auckland, 1023, New Zealand
Ascendis Investigational Site
RECRUITING

Oslo, 0372, Norway
Ascendis Investigational Site
RECRUITING

Coimbra, 3000-602, Portugal
Ascendis Investigational Site
RECRUITING

Stockholm, 17176, Sweden
Ascendis Investigational Site
RECRUITING

London, SE1 7EH, United Kingdom

Conditions

Explore the condition pages connected to this study.

ACHONDROPLASIA